T
TherapeuticsMD, Inc.
TXMDCIK 0000025743NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-569.0K
Total Assets
$37.66M
Equity
$26.88M
Shares Out
11.57M
Op. Cash Flow
$2.45M
Business
TherapeuticsMD, Inc. is a pharmaceutical royalty company that receives royalties and contingent payments from third-party licensees that commercialize its former product portfolio. Its main products consist of licensed women’s health pharmaceutical products, including IMVEXXY, BIJUVA, ANNOVERA, and prescription prenatal vitamin lines. The company’s key activities include licensing and intellectual property management, oversight of royalty-bearing products, and administration of partner agreements following the transition away from direct commercial operations. Distribution and markets are primarily through exclusive licensees: Mayne Pharma in the U.S. and partners (Knight, Theramex) for Canada, Israel and other international territories.
Summary from filing dated 2025-03-27
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| License revenue | 3 | 2 | — | — | — | |
| General and administrative | 7 | 6 | 9 | 57 | 81 | |
| Write-off and impairment of patents | 176,000 | 1 | — | — | — | |
| Depreciation & amortization | 384,000 | 509,000 | 922,000 | 1 | — | |
| Total operating expenses | 7 | 8 | 10 | 67 | 81 | |
| Loss from operations | −4 | −6 | −9 | 1 | −80 | |
| Interest income, net | 142,000 | 135,000 | — | — | — | |
| Sublease income | 2 | 1 | — | — | — | |
| Miscellaneous income | 2 | 2 | 781,000 | — | — | |
| Total other income | 4 | 4 | 781,000 | −117,000 | 272,000 | |
| Loss from continuing operations before income taxes | −653,000 | −2 | −8 | 1 | −79 | |
| Income tax benefit | — | 31,000 | 43,000 | — | — | |
| Net loss from continuing operations | −653,000 | −2 | −8 | 1 | −79 | |
| Income from discontinued operations, net of income taxes | 84,000 | 131,000 | −3 | 111 | — | |
| Net loss | −569,000 | −2 | −10 | 112 | −172 | |
| Continuing operations (in Dollars per share) | −0.06 | −0.2 | −0.74 | 0.12 | −9.96 | |
| Discontinued operations, net (in Dollars per share) | 0.01 | 0.01 | −0.25 | 12.29 | −11.7 | |
| Net loss per common share, basic (in Dollars per share) | −0.05 | −0.19 | −0.99 | 12.41 | −21.66 | |
| Continuing operations (in Dollars per share) | −0.06 | −0.2 | −0.74 | 0.11 | −9.96 | |
| Discontinued operations, net (in Dollars per share) | 0.01 | 0.01 | −0.25 | 11.84 | −11.7 | |
| Net loss per common share, diluted (in Dollars per share) | −0.05 | −0.19 | −0.99 | 11.96 | −21.66 | |
| Weighted average common shares, basic (in Shares) | 12 | 12 | 10,441 | 9 | 8 | |
| Weighted average common shares, diluted (in Shares) | 12 | 12 | 10,441 | 9 | 8 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 5 | — | — | — | |
| Royalty receivable, current portion | 4 | 4 | 3 | — | — | |
| Prepaid and other current assets | 3 | 4 | 4 | 6 | 6 | |
| Total current assets | 14 | 12 | 12 | 55 | 119 | |
| License rights and other intangible assets, net | 4 | 4 | 6 | 7 | 7 | |
| Right of use assets, net | 5 | 6 | 7 | 8 | 8 | |
| Royalty receivable, long term | 14 | 16 | 18 | 20 | — | |
| Other non-current assets | 444,000 | 130,000 | 58,000 | 253,000 | 253,000 | |
| Total assets | 38 | 39 | 43 | 90 | 169 | |
| Accounts payable | 377,000 | 258,000 | 27,000 | 2 | 3 | |
| Accrued expenses and other current liabilities | 2 | 2 | 3 | — | — | |
| Current liabilities of discontinued operations | 3 | 3 | 4 | 26 | 48 | |
| Total current liabilities | 5 | 5 | 7 | 47 | 253 | |
| Operating lease liabilities | 5 | 6 | 7 | 7 | 8 | |
| Other non-current liabilities | 873,000 | 744,000 | 636,000 | 1 | 2 | |
| Total liabilities | 11 | 11 | 14 | 55 | 263 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Common stock, par value $0.001; 32,000 and 32,000 shares authorized, 11,574 and 11,532 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 11,000 | 11,000 | 11,000 | 9,000 | 9,000 | |
| Additional paid-in capital | 979 | 979 | 979 | 974 | 958 | |
| Accumulated deficit | −952 | −952 | −950 | −939 | −1,051 | |
| Total stockholders equity | 27 | 27 | 29 | 35 | −94 | |
| Total liabilities and stockholders equity | 38 | 39 | 43 | 90 | 169 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Write-off and impairment of patents | 176,000 | 1 | — | — | — | |
| Share-based payment compensation costs | 75,000 | 264,000 | 1 | 12 | 18 | |
| Amortization of right of use assets | 809,000 | 771,000 | — | — | — | |
| Prepaid and other current assets | 201,000 | 397,000 | 2 | 620,000 | −1 | |
| Other assets | 2 | 2 | −1 | — | — | |
| Accounts payable | 119,000 | 231,000 | −2 | −1 | −1 | |
| Accrued expenses and other current liabilities | 272,000 | −1 | −16 | 4 | 5 | |
| Lease liabilities | −1 | −990,000 | — | — | — | |
| Other non-current liabilities | 129,000 | 108,000 | −471,000 | −121,000 | 2 | |
| Total adjustments | 3 | 3 | −15 | 8 | 24 | |
| Net cash provided by continuing operating activities | 2 | 1 | −23 | 9 | −55 | |
| Net cash used in operating activities | −30,000 | −438,000 | −25 | −13 | −88 | |
| Net cash used in discontinued operations | −30,000 | −438,000 | −25 | 210 | −88 | |
| Net increase in cash | 2 | 732,000 | −45 | −16 | −15 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro